Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials

Feb 01 2017

• By Emily Hayes

3d render illustration of human digestive system - front view

Related Content

Well-Funded Seres Races To Be First To Market With A Microbiome Drug

Aug 28 2015

Pfizer To Take Zinplava Rival Into Phase III For C Diff

Jan 30 2017

Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning

Oct 26 2016

Related Companies

Seres Therapeutics, Inc.

Merck & Co., Inc.

Sanofi

Valneva SE

Additional Topics

Clinical Trials Regulation Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.